A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
Latest Information Update: 23 Jun 2026
At a glance
- Drugs Indapamide/Levamlodipine/valsartan-Ahn-Gook-Pharmaceuticals (Primary) ; Levamlodipine/valsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Ahn-Gook Pharmaceutical
Most Recent Events
- 18 Jun 2026 Status changed from not yet recruiting to completed.
- 24 Aug 2022 New trial record